Skip to content

    Research Use Only

    This site is an educational resource for research compounds. We do not endorse human consumption of any compound. BodyHackGuide and BHG Labs share common ownership; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide

    P-21 Amidate

    Nootropic PeptidePreclinical

    Also known as: P21 Amide, P-21 Amide, P-21-NH2, Cyclo-Pro-Gly-Amide

    P-21 Amidate is the amide-modified variant of P-21, the cyclic dipeptide derived from Selank. The C-terminal amidation is reported to further improve oral bioavailability and metabolic stability beyond what the cyclic structure alone provides. The practical positioning: P-21 is already orally active; the amidate variant pushes that further, with vendor and community reports of higher subjective potency at equivalent doses.

    Half-Life: No established human PK - unknown. P-21 (P021) is a preclinical compound; rodent studies used chronic oral or subcutaneous dosing and demonstrated oral bioavailability and blood-brain-barrier penetration, but no validated human half-life data exist.MW: ~592.7 g/mol (free base; molecular formula C28H44N6O8)1 PubMed Studies
    Last reviewed:

    Overview

    At A Glance

    Mechanism

    Mechanism (P-21 / P021):

    Half-Life
    No established human PK - unknown. P-21 (P021) is a preclinical compound; rodent studies used chronic oral or subcutaneous dosing and demonstrated oral bioavailability and blood-brain-barrier penetration, but no validated human half-life data exist.

    Mechanism of Action

    Mechanism (P-21 / P021):

    P-21 is a small-molecule mimetic of a biologically active region of human ciliary neurotrophic factor (CNTF) - an adamantylated peptide amide, Ac-DGGL(A)G-NH2. Its reported actions come from preclinical (rodent) studies:

    • Increases brain-derived neurotrophic factor (BDNF) expression by inhibiting the leukemia inhibitory factor (LIF) signaling pathway [PMID:27400746]
    • Enhances hippocampal (dentate gyrus) neurogenesis and synaptic plasticity [PMID:25046994]
    • Lowers tau hyperphosphorylation indirectly: increased BDNF reduces glycogen synthase kinase-3 (GSK-3, a major tau kinase) activity [PMID:27400746]
    • Blood-brain-barrier permeable and orally bioavailable, unlike native CNTF or BDNF [PMID:27400746]

    On the "Amidate" label: Base P021 is already C-terminally amidated (the -NH2 in Ac-DGGL(A)G-NH2). Vendor claims that "P-21 Amidate" is a chemically distinct, more stable, or more potent form than standard P-21 are unverified marketing differentiation and are not supported by the published literature.

    All evidence is from animal models - there are no human pharmacokinetic, efficacy, or safety studies. Research use only.

    Overview

    P-21 Amidate is the amide-modified variant of P-21, the cyclic dipeptide derived from Selank. The C-terminal amidation is reported to further improve oral bioavailability and metabolic stability beyond what the cyclic structure alone provides.

    The practical positioning: P-21 is already orally active; the amidate variant pushes that further, with vendor and community reports of higher subjective potency at equivalent doses. Peer-reviewed comparative data for the amidate form remains thin — most published P-21 research uses the unmodified cyclic form.

    Chemical Information

    IUPAC Name

    Not yet available

    CAS Number

    Not yet available

    Molecular Formula

    C7H11N3O2

    Molecular Mass

    592.69 g/mol

    Amino Acid Sequence

    Ac-DGGL(A)G-NH2

    Dosing & Protocols

    Unlock Dosing Protocols

    Free account gets you:

    • View beginner, intermediate & advanced protocols
    • See weight-based dosing calculations
    • Access cycle length & frequency data

    2,800+ researchers already in

    Research

    Unlock Research Data

    Free account gets you:

    • Browse PubMed study summaries
    • See clinical trial phases & results
    • Access mechanism of action details

    2,800+ researchers already in

    Interactions

    Interaction and contraindication data is being compiled for P-21 Amidate. Check back soon.

    General Safety Note

    Always consult a qualified healthcare professional before combining research compounds. Interactions may exist that are not yet documented.

    No listings found for P-21 Amidate.

    Get P-21 Amidate Price Drop Alerts

    Set a target price and we'll notify you when any vendor drops below it.

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with P-21 Amidate.

    Related Compounds

    View All

    Adalank

    Nootropic PeptidePreclinical / Research compound

    Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog).

    t½ The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data. 200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily
    PreclinicalView Profile

    Adamax

    Nootropic PeptidePreclinical / Research compound

    Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.

    t½ No pharmacokinetic data. Community reports describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; serum half-life not characterized. 500-2000 mcg subcutaneous (community research dosing)
    PreclinicalView Profile

    Cerebrolysin

    Nootropic PeptideClinical

    Cerebrolysin is a porcine brain-derived peptide complex developed by EVER Neuro Pharma (Austria) — a low-molecular-weight neurotrophic preparation containing a mixture of free amino acids and bioactive peptides extracted from purified pig brain proteins.

    t½ ~2-4 hours (multi-component peptide mix)
    85 studiesView Profile

    Cortexin

    Nootropic PeptideMarketed in Russia/CIS (Geropharm); human clinical use with limited-quality evidence (small, mostly Russian-language studies; no Western RCT; not FDA/EMA approved)

    Cortexin is a purified peptide preparation extracted from cattle and pig cerebral cortex tissue — a low-molecular-weight neuropeptide complex used clinically in Russia and Eastern Europe for cognitive impairment, post-stroke recovery, encephalopathy, attention disorders, and pediatric developmental conditions. Like Cerebrolysin, Cortexin is positioned as a broad-spectrum neurotrophic preparation supplying bioactive peptides that mimic endogenous neurotrophic factors.

    t½ ~2-3 hours (estimated from analog peptide preparations)
    18 studiesView Profile

    NA-Semax

    Nootropic PeptidePreclinical

    NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s.

    t½ ~20-30 minutes (intranasal, estimated from analog data)
    3 studiesView Profile

    NA-Semax Amidate

    Nootropic PeptidePreclinical

    NA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency use: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule.

    t½ ~30-45 minutes (estimated, longer than standard Semax)
    2 studiesView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for P-21 Amidate

    Research Score

    60

    1 PubMed studies

    Quality Indicators

    Data Completeness

    75%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Studies
    Interactions
    Vendor Listings

    Research Credibility

    1PubMed studies

    Limited research available

    Quick Facts

    Half-Life

    No established human PK - unknown. P-21 (P021) is a preclinical compound; rodent studies used chronic oral or subcutaneous dosing and demonstrated oral bioavailability and blood-brain-barrier penetration, but no validated human half-life data exist.

    Molecular Weight

    592.69 g/mol

    Trial Phase

    Preclinical

    Safety Profile

    Moderate Risk

    Stop Use If

    • Pregnancy or breastfeeding
    • Known peptide allergy

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    What is P-21 Amidate used for in research?

    P-21 Amidate is the amide-modified variant of P-21, the cyclic dipeptide derived from Selank. The C-terminal amidation is reported to further improve oral bioavailability and metabolic stability beyond what the cyclic structure alone provides.

    The practical positioning: P-21 is already orally active; the amidate variant pushes that further, with vendor and community reports of higher subjective potency at equivalent doses. Peer-reviewed comparative data for the amidate form remains thin — most published P-21 research uses the unmodified cyclic form.

    What forms does P-21 Amidate come in?

    P-21 Amidate is available in vials, capsules, and sprays forms.

    How much does P-21 Amidate cost?

    Pricing varies by vendor and form.

    How do I compare P-21 Amidate vendors?

    Compare prices, payment methods, shipping, and COA scores across 0 vendors.

    Research Tools

    Related Compounds

    View All

    Adalank

    Nootropic PeptidePreclinical / Research compound

    Adalank is a hybrid research peptide combining structural elements of Adamax (the adamantyl-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog).

    t½ The commonly cited ~72-hour "functional duration" is an unverified community/vendor claim, not a measured value - no pharmacokinetic study of Adalank has ever been run. The figure is extrapolated from parent Adamax marketing claims. Actual serum half-life is unknown; there is no published PK data. 200-1200 mcg per dose (intranasal or subcutaneous), 1-2x daily
    PreclinicalView Profile

    Adamax

    Nootropic PeptidePreclinical / Research compound

    Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.

    t½ No pharmacokinetic data. Community reports describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; serum half-life not characterized. 500-2000 mcg subcutaneous (community research dosing)
    PreclinicalView Profile

    Cerebrolysin

    Nootropic PeptideClinical

    Cerebrolysin is a porcine brain-derived peptide complex developed by EVER Neuro Pharma (Austria) — a low-molecular-weight neurotrophic preparation containing a mixture of free amino acids and bioactive peptides extracted from purified pig brain proteins.

    t½ ~2-4 hours (multi-component peptide mix)
    85 studiesView Profile

    Cortexin

    Nootropic PeptideMarketed in Russia/CIS (Geropharm); human clinical use with limited-quality evidence (small, mostly Russian-language studies; no Western RCT; not FDA/EMA approved)

    Cortexin is a purified peptide preparation extracted from cattle and pig cerebral cortex tissue — a low-molecular-weight neuropeptide complex used clinically in Russia and Eastern Europe for cognitive impairment, post-stroke recovery, encephalopathy, attention disorders, and pediatric developmental conditions. Like Cerebrolysin, Cortexin is positioned as a broad-spectrum neurotrophic preparation supplying bioactive peptides that mimic endogenous neurotrophic factors.

    t½ ~2-3 hours (estimated from analog peptide preparations)
    18 studiesView Profile

    NA-Semax

    Nootropic PeptidePreclinical

    NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s.

    t½ ~20-30 minutes (intranasal, estimated from analog data)
    3 studiesView Profile

    NA-Semax Amidate

    Nootropic PeptidePreclinical

    NA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency use: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule.

    t½ ~30-45 minutes (estimated, longer than standard Semax)
    2 studiesView Profile

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.